A Phase 4 interventional study of Ketamine and Midazolam in Suicidal Ideation, sponsored by James Murrough. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-08.
Sponsored by James Murrough · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing ketamine in Suicidal Ideation — 8 open to participants now, 9 under way, 3 of them phase 3. Ketamine · Suicidal Ideation.
Among the 36 studies testing ketamine in Suicidal Ideation, this one is the 17th largest by enrollment, is one of 4 that started in 2012, is one of 8 in phase 4, and was the 1st registered.
570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.
Browse Suicidal Ideation studies →8 of the 36 studies testing ketamine in Suicidal Ideation are open now, in 2 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–70
Joshua Rosenblat · Sites in Canada
Ages 18–70
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Lindsay Maguire, MD · Sites in United States
Ages 18–65
Children's Hospital of Eastern Ontario · Sites in Canada
Ages 12–17
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 135 Suicidal Ideation studies recruiting now, 52 (39%) set no upper age limit and 79 (59%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 12 · Phase 3 7 · Phase 4 8
First in 2012; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 470 interventional studies indexed under Suicidal Ideation.
Median enrollment 22 across the 36 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 36 have an industry lead sponsor. The 10 most frequent:
James Murrough is the lead sponsor of 9 studies on the registry; none are open to participants now.
James Murrough has 1 study filed under Suicidal Ideation — fewer than ten, so there is no comparison to draw.
4 of the studies testing ketamine in Suicidal Ideation that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05696691Phase 3The University of Texas Health Science Center at San AntonioKetamine & Crisis Response Plan for Suicidal Ideation in the ED | 2026-12-31 |
| NCT06891300Phase 3The Royal's Institute of Mental Health ResearchUnderstanding and Treating Suicidal Ideation With Ketamine | 2027-03 |
| NCT07810023Endeavor HealthIntramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress | 2027-03 |
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing ketamine in Suicidal Ideation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).
Depression is a debilitating disorder that affects 12-20% of population and is among the top five leading causes of burden of disease worldwide (Kruijshaar ME 2005). Suicide associated with depression and other psychiatric disorders is a pervasive public health problem and results in almost one million deaths per year. Unfortunately, current treatments for severe depression have limited efficacy for suicidality, specifically due to the slow time course of change in suicidal thoughts. Recently ketamine, a glutamate-modulating agent, was shown to have antidepressant and anti-suicidal effect in outpatient depressed patients. The proposed study will test the ability of a single sub-anesthetic intravenous (IV) dose of the glutamate NMDA receptor antagonist, ketamine, to provide rapid decrease in suicidal ideation (SI) in patients hospitalized with SI. In this randomized parallel-arm placebo controlled trial, ketamine is compared to midazolam, which is expected to mimic some of the acute subjective effects of ketamine but not have any sustained antidepressant effects.
Specific Aim 1: To determine feasibility and tolerability of a single low-dose IV infusion of ketamine in patients with prominent SI and elevated risk for suicide.
Hypothesis 1: Ketamine administration will be feasible and well tolerated in patients admitted to a psychiatric hospital with SI.
Specific Aim 2: To test the efficacy of a single IV dose of ketamine, compared to an anesthetic control condition (midazolam), to rapidly reduce SI in a controlled hospital setting.
Hypothesis 2: Ketamine will be associated with significant and rapid reductions in SI and depressive symptoms within 24 hours.
This study will test the rapid anti-suicidal effect of a single IV dose of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine in suicidality compared with the clinical response to a single IV dose of the short-acting benzodiazepine midazolam. Midazolam is able to induce transient neuropsychiatric effects mimicking ketamine and therefore is expected to protect the integrity of the blind. Participants will continue to receive standard treatment for their psychiatric condition throughout the trial. This unique "proof-of-concept" study in suicidal patients will be conducted over three-year period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose IV ketamine, .5mg/kg
Drug: Ketamine
single dose IV midazolam, .45mg/kg
Drug: Midazolam
single dose IV ketamine, .5mg/kg infused over 40 minutes
Also known as: N-methyl-D-aspartate (NMDA) glutamate receptor antagonist
single dose IV midazolam, .45mg/kg infused over 40 minutes
Change in Beck Scale for Suicidal Ideation (BSSI)
Change in BSI score at 24 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.
Time frame: baseline and 24 hours post infusion
Change in Beck Scale for Suicidal Ideation (BSSI)
Change in BSI score at 48 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.
Time frame: baseline and 48 hours post infusion
Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.
Time frame: up to 7 days post infusion
Suicidality Item of the MADRS (MADRS-SI)
The MADRS-SI ranges from 0 to 6; a score of 2 corresponds to fleeting, passive SI; a score of 4 indicates that SI is frequent with at least moderate intensity but without specific plans or intention; a score of 6 corresponds to active intention and planning for suicide.
Time frame: 24 hours post infusion
The Young Mania Rating Scale (YMRS)
An 11-item questionnaire, used to assess manic symptoms based on the patient's subjective report of his or her clinical condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms.
Time frame: baseline, 40 minutes post infusion, 240 minutes post infusion
The Brief Psychiatric Rating Scale (BPRS)
The BPRS measures psychomimetic effects with higher scores indicating more severe symptoms (scale range 7 - 49).
Time frame: baseline, 40 minutes post infusion, and 240 minutes post infusion
The Clinician-Administered Dissociative States Scale (CADSS)
The CADSS measures dissociation with higher scores indicating more severe symptoms (scale range 0 - 92).
Time frame: baseline, 40 minutes post infusion and 240 minutes post infusion
Patient Rated Inventory of Side Effects (PRISE)
The PRISE assesses the presence of treatment side effects in nine organ/function systems (gastrointestinal, nervous system, heart, eyes/ears, skin, genital/urinary, sleep, sexual functioning, and other). Data reported in in Adverse Events section.
Time frame: duration of study
Participants were recruited through the inpatient psychiatric service or through an academic outpatient psychiatric clinic. All study treatments were performed at Mount Sinai Hospital between April 2012 and June 2014.
| Milestone | Ketamine | Midazolam |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
Change in BSI score at 24 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.
| units on a scale | Ketamine | Midazolam |
|---|---|---|
| Change in Beck Scale for Suicidal Ideation (BSSI) | 10.8 ± 8.5 | 14.0 ± 10.2 |
Change in BSI score at 48 hours following treatment as compared to baseline. Beck Scale is a 21-item self or clinician administered instrumentation used to measure the current intensity of patients' specific attitudes, behaviors and plans to commit suicide. Score range 0-42, with higher score indicating higher intensity.
| units on a scale | Ketamine | Midazolam |
|---|---|---|
| Change in Beck Scale for Suicidal Ideation (BSSI) | 8.8 ± 8.3 | 15.3 ± 10.9 |
The MADRS is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.
| units on a scale | Ketamine | Midazolam |
|---|---|---|
| 24 hours | 19.0 ± 15.5 | 26.2 ± 10.8 |
| 48 hours | 19.3 ± 13.5 | 28 ± 12.3 |
| 72 hours | 20.9 ± 14.5 | 24.1 ± 12.2 |
| 7 days | 21.7 ± 13.1 | 22.2 ± 13.1 |
The MADRS-SI ranges from 0 to 6; a score of 2 corresponds to fleeting, passive SI; a score of 4 indicates that SI is frequent with at least moderate intensity but without specific plans or intention; a score of 6 corresponds to active intention and planning for suicide.
| units on a scale | Ketamine | Midazolam |
|---|---|---|
| Suicidality Item of the MADRS (MADRS-SI) | 1.8 ± 1.9 | 3.3 ± 1.6 |
An 11-item questionnaire, used to assess manic symptoms based on the patient's subjective report of his or her clinical condition. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms.
| units on a scale | Ketamine | Midazolam |
|---|---|---|
| baseline | 0.0 ± 0.0 | 0.1 ± 0.3 |
| 40 minutes post infusion | 0.0 ± 0.0 | 0.3 ± 0.6 |
| 240 minutes post infusion | 0.2 ± 0.6 | 0.2 ± 0.6 |
The BPRS measures psychomimetic effects with higher scores indicating more severe symptoms (scale range 7 - 49).
| units on a scale | Ketamine | Midazolam |
|---|---|---|
| baseline | 7.7 ± 1.12 | 7.7 ± 1.3 |
| 40 minutes post infusion | 9.9 ± 3.3 | 7.9 ± 1.8 |
| 240 minutes post infusion | 8.1 ± 1.6 | 7.0 ± 0.1 |
The CADSS measures dissociation with higher scores indicating more severe symptoms (scale range 0 - 92).
| units on a scale | Ketamine | Midazolam |
|---|---|---|
| baseline | 1.1 ± 2.6 | 4.0 ± 7.0 |
| 40 minutes post infusion | 17.1 ± 19.9 | 3.3 ± 3.1 |
| 240 minutes post infusion | 1.2 ± 1.9 | 1.3 ± 2.6 |
The PRISE assesses the presence of treatment side effects in nine organ/function systems (gastrointestinal, nervous system, heart, eyes/ears, skin, genital/urinary, sleep, sexual functioning, and other). Data reported in in Adverse Events section.
| events | Ketamine | Midazolam |
|---|---|---|
| Patient Rated Inventory of Side Effects (PRISE) | 29 | 23 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ketamine | — | 5/12 (41.7%) | 12/12 (100%) |
| Midazolam | — | 0/12 (0%) | 12/12 (100%) |
| Event | Ketamine | Midazolam |
|---|---|---|
| HospitalizationsPsychiatric disorders | 4/12 | 0/12 |
| DeathRespiratory, thoracic and mediastinal disorders | 1/12 | 0/12 |
| Event | Ketamine | Midazolam |
|---|---|---|
| HeadacheNervous system disorders | 7/12 | 3/12 |
| Dizziness on standingNervous system disorders | 2/12 | 3/12 |
| Nausea/VomitingGeneral disorders | 1/12 | 3/12 |
| DiarrheaGeneral disorders | 0/12 | 3/12 |
| AnxietyPsychiatric disorders | 2/12 | 2/12 |
| Poor concentrationGeneral disorders | 2/12 | 1/12 |
| Poor coordinationNervous system disorders | 2/12 | 0/12 |
| General malaiseGeneral disorders | 2/12 | 0/12 |
| RestlessnessGeneral disorders | 2/12 | 0/12 |
| Dry mouthGeneral disorders | 0/12 | 2/12 |
| Age, Continuous(years) | Ketamine | Midazolam | Total |
|---|---|---|---|
| Mean | 45.8 ± 15.2 | 39.1 ± 10.6 | 42.4 ± 13.3 |
| Gender(Participants) | Ketamine | Midazolam | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 4 | 4 | 8 |
| History of suicide attempt(participants) | Ketamine | Midazolam | Total |
|---|---|---|---|
| yes | 6 | 9 | 15 |
| no | 6 | 3 | 9 |
| BSI score, baseline(units on a scale) | Ketamine | Midazolam | Total |
|---|---|---|---|
| Mean | 17.5 ± 7.2 | 17.9 ± 11.9 | 17.7 ± 9.7 |
| MADRS score, baseline(units on a scale) | Ketamine | Midazolam | Total |
|---|---|---|---|
| Mean | 35.2 ± 6.1 | 34.3 ± 4.1 | 34.8 ± 5.1 |
| Primary Diagnosis(participants) | Ketamine | Midazolam | Total |
|---|---|---|---|
| MDD | 6 | 7 | 13 |
| Bipolar disorder | 4 | 3 | 7 |
| PTSD | 1 | 2 | 3 |
| BPD | 1 | 0 | 1 |
| Co-occurring disorders(participants) | Ketamine | Midazolam | Total |
|---|---|---|---|
| MDD | 2 | 2 | 4 |
| PTSD | 2 | 1 | 3 |
| BPD | 1 | 0 | 1 |
| Panic disorder | 3 | 1 | 4 |
| SAD | 2 | 4 | 6 |
| OCD | 3 | 3 | 6 |
| GAD | 5 | 1 | 6 |
The record gives a start of Jan 2012, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine
James Murrough